Nightstar Therapeutics PLC Sponsored ADR (NASDAQ:NITE) has been given an average broker rating score of 1.00 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy rating.

Brokerages have set a one year consensus price target of $24.75 for the company, according to Zacks. Zacks has also assigned Nightstar Therapeutics PLC Sponsored ADR an industry rank of 167 out of 265 based on the ratings given to related companies.

Several research firms have recently commented on NITE. Leerink Swann began coverage on Nightstar Therapeutics PLC Sponsored ADR in a research note on Monday, October 23rd. They set an “outperform” rating and a $25.00 target price for the company. Wedbush began coverage on Nightstar Therapeutics PLC Sponsored ADR in a research note on Monday, October 23rd. They set an “outperform” rating and a $19.00 target price for the company. Jefferies Group LLC began coverage on Nightstar Therapeutics PLC Sponsored ADR in a research note on Monday, October 23rd. They set a “buy” rating and a $25.00 target price for the company. Finally, BMO Capital Markets began coverage on Nightstar Therapeutics PLC Sponsored ADR in a research note on Monday, October 23rd. They set an “outperform” rating and a $30.00 target price for the company.

COPYRIGHT VIOLATION WARNING: “Zacks: Nightstar Therapeutics PLC Sponsored ADR (NITE) Given Average Rating of “Strong Buy” by Brokerages” was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/11/03/zacks-nightstar-therapeutics-plc-sponsored-adr-nite-given-average-rating-of-strong-buy-by-brokerages.html.

An institutional investor recently bought a new position in Nightstar Therapeutics PLC Sponsored ADR stock. Nationwide Fund Advisors bought a new stake in shares of Nightstar Therapeutics PLC Sponsored ADR (NASDAQ:NITE) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 62,300 shares of the company’s stock, valued at approximately $1,196,000. Nationwide Fund Advisors owned about 0.22% of Nightstar Therapeutics PLC Sponsored ADR at the end of the most recent quarter. Institutional investors own 0.23% of the company’s stock.

Shares of Nightstar Therapeutics PLC Sponsored ADR (NASDAQ NITE) traded down $0.21 during mid-day trading on Friday, hitting $22.78. 48,583 shares of the stock traded hands, compared to its average volume of 94,491.

Nightstar Therapeutics PLC Sponsored ADR Company Profile

Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases.

Get a free copy of the Zacks research report on Nightstar Therapeutics PLC Sponsored ADR (NITE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Nightstar Therapeutics PLC Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics PLC Sponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.